Regulators and Labs Push Alternatives to Animal Testing
Advanced nonanimal methods (NAMs) such as organ‑on‑a‑chip systems, organoids, and computational models are maturing and are being adopted by some drug developers and regulators. But validation, standardization, data sharing, funding, and cultural change remain major barriers to wider use.